# Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)

> **NCT07224009** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University of Arkansas** · enrollment: 60 (estimated)

## Conditions studied

- Metastatic Prostate Cancer

## Interventions

- **DRUG:** Naltrexone

## Key facts

- **NCT ID:** NCT07224009
- **Lead sponsor:** University of Arkansas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2028-01
- **Final completion:** 2029-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07224009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07224009, "Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07224009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*